CGT Bioprocessing Market Outlook 2026–2036: Market Size, Growth Drivers, Key Players, Strategic Developments & Adoption Forecast for Closed Automated Cell Therapy Platforms, Viral Vector and Plasmid Supply, CDMO Capacity, Decentralised Manufacturing and FDA CMC Flexibility — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines how cell and gene therapy manufacturing — the closed automated platforms, single-use systems, viral vector and plasmid supply, analytics and contract capacity that turn a patient's cells or a genetic construct into a released dose — will industrialise over the next ten years, as the field moves from skilled manual processing in open suites toward standardised, automated and increasingly decentralised production. The turn is visible in 2026. Cellares raised a USD 257 million Series D on 28 January 2026 led by BlackRock and Eclipse, later extended to about USD 327 million with USD 50 million from Prime Radiant Partners, to build automated Smart Factories in South San Francisco, Bridgewater, Leiden and Kashiwa; in April 2026 the first therapies made on its Cell Shuttle for a paying customer were infused into patients, following the platform's first-ever FDA Advanced Manufacturing Technology designation in April 2025, a USD 380 million Bristol Myers Squibb agreement, a ten-year supply agreement with Cabaletta Bio and selection for the FDA PreCheck pilot in June 2026. The FDA posted its flexible approach to chemistry, manufacturing and controls for cell and gene therapies on 11 January 2026, finalised the guidance on 8 May 2026 and issued a draft on reusing prior knowledge for genome-editing products on 2 June 2026. At the same time conventional capacity is being withdrawn: Catalent is closing its Gosselies cell therapy centre with about 150 staff, Charles River announced the closure of its Hanover cell therapy site on 6 February 2026, Thermo Fisher cut 300 viral vector jobs and AmplifyBio shut down. AstraZeneca is evaluating Multiply Labs' robotic systems, which raised USD 75 million in 2026, and Galapagos is running decentralised CAR-T on Lonza Cocoon units near cancer centres with Blood Centers of America. The brief maps the technology, its indicative market size and forecast, the factors behind its growth, the developments of the last 24 months, the key players operating in the space and the adoption trajectory to 2036.

It is a focused 110-page decision brief for contract manufacturers, pharmaceutical and biotechnology companies, equipment and consumables suppliers, hospital manufacturing centres, regulators and investors. It presents an indicative trajectory rather than a segmented market model. Its purpose is to identify which manufacturing models and technologies scale, how regulation, automation and demand set the pace, and who captures value as cell and gene therapy production becomes an industry.

Cell and gene therapy manufacturing covers four linked activities. Autologous cell processing takes a patient's apheresis product through isolation, activation, genetic modification, expansion, formulation and cryopreservation — historically in open or semi-closed steps by skilled operators, which the Alliance for Regenerative Medicine's November 2025 workshop paper identified as the field's central constraint. Allogeneic and stem cell processes scale donor or induced pluripotent cells into many doses. Vector and material supply produces lentiviral and AAV vectors, plasmids, mRNA and non-viral delivery reagents. Release testing and batch records close the loop. Automation now addresses the first and last: Cellares' Cell Shuttle runs a standardised, closed, end-to-end process with Cell Q release assays, Lonza's Cocoon runs a closed single-patient process that Galapagos has placed near cancer centres, and Multiply Labs' robotic systems, under evaluation by AstraZeneca, automate conventional unit operations.

The regulatory environment has moved with the technology. The FDA's first Advanced Manufacturing Technology designation went to the Cell Shuttle in April 2025; CBER's flexible CMC approach, posted in January 2026 and finalised as guidance on 8 May 2026, confirms that early lots need not meet full cGMP, that specifications can follow development stage, that comparability is risk-based and that there is no fixed three-lot validation requirement; the June 2026 draft on genome-editing knowledge reuse and the Platform Technology Designation under FDORA allow data to carry across products; and the PreCheck pilot brings facility readiness discussions forward. Automated platforms have now dosed patients for paying customers under this framework.

The constraints are demand concentration, capital, vector supply and the overhang of conventional capacity. Commercial cell therapy volumes remain concentrated in a few CAR-T and gene therapy products; Catalent, Charles River, Thermo Fisher and AmplifyBio have closed or cut conventional sites on weak demand while Novo Nordisk, Takeda and Caribou have exited programmes; viral vector cost and lead time remain high; and the automated model's claim of ten conventional facilities' output from one Smart Factory is not yet proven at commercial throughput. The decade's question is whether automation and regulatory flexibility cut cost of goods fast enough to widen demand before capacity is written off.

The CGT bioprocessing market — cell and gene therapy manufacturing equipment and automation platforms, single-use consumables, viral vector, plasmid and delivery materials, and contract development and manufacturing services, excluding the therapies themselves and general biologics bioprocessing — is estimated at USD 14–18 billion in 2026, led by contract manufacturing at Lonza, Thermo Fisher, Catalent, Charles River, WuXi Advanced Therapies, SK pharmteco and Samsung Biologics, by consumables and equipment from Cytiva, Sartorius, Miltenyi Biotec, Thermo Fisher and Terumo, by vector and plasmid supply and by automated platform operators. Meticulous Next™ expects it to reach USD 55–75 billion by 2036, an indicative CAGR of 14–16%. Growth is driven by automated closed platforms moving to commercial scale from 2027, by FDA CMC flexibility and platform designations that shorten development, by expansion of autologous therapies into autoimmune disease, by gene-edited stem cell and in vivo programmes, by decentralised and hospital manufacturing and by cost of goods reduction that widens eligible populations. The forecast is sensitive to commercial cell therapy demand, vector cost and the pace at which conventional capacity is retired. The United States leads on platforms, regulation and capital; Europe hosts Lonza, Sartorius, Miltenyi and the Leiden Smart Factory; Japan, South Korea and Singapore add capacity and investment; China's capacity serves domestic programmes.

The base case assumes Smart Factory commercial capacity in 2027, first platform-based approvals by 2030 and autoimmune CAR-T adding meaningful volume from 2029. An accelerated case adds rapid autoimmune and in vivo demand, early decentralised licensing and faster vector cost declines, bringing the inflection to 2029 and lifting the 2036 value to the top of the range. A delayed case assumes slower commercial demand, automated throughput below claims and prolonged vector constraints, keeping growth at the bottom of the range with further conventional site closures.

Growth drivers

• Automated closed platforms in clinical manufacturing with first paying-customer doses infused (April 2026) and commercial capacity planned for 2027.
• FDA flexible CMC approach (January 2026), final guidance (May 2026), genome-editing knowledge-reuse draft (June 2026), AMT and Platform Technology designations and the PreCheck pilot.
• Capital for automation: Cellares USD 257 million Series D extended to about USD 327 million; Multiply Labs USD 75 million; AstraZeneca and Bristol Myers Squibb commitments.
• Expansion of autologous therapies into autoimmune disease and of gene-edited stem cell programmes.

Enablers

• Standardised platform processes and release assays (Cell Shuttle, Cell Q, Cocoon).
• Decentralised networks: Galapagos with Blood Centers of America's 50-plus centres, Landmark Bio and Thermo Fisher sites near treatment centres.
• Single-use, modular and robotic equipment from Cytiva, Sartorius, Miltenyi, Terumo and Multiply Labs.
• Industry coordination through the Alliance for Regenerative Medicine's advanced manufacturing agenda (November 2025).

Restraints and barriers

• Concentrated commercial demand and programme exits (Novo Nordisk, Takeda, Caribou).
• Conventional CDMO overcapacity: Catalent Gosselies and Charles River Hanover closures, Thermo Fisher viral vector cuts, AmplifyBio shutdown.
• Viral vector cost, lead time and supply; high cost of goods per autologous dose.
• Automated throughput claims unproven at commercial scale; skilled workforce still required for process development.

Five converging forces will determine whether, and how fast, cell and gene therapy manufacturing industrialises: (1) closed automated platforms reaching commercial throughput; (2) FDA and EMA flexibility on CMC, platforms and facility readiness; (3) demand diversification into autoimmune, stem cell and in vivo programmes; (4) decentralised and hospital-based production; and (5) consolidation of conventional CDMO capacity. The brief assesses each force for direction, speed and confidence.

The key players operating in CGT bioprocessing include Cellares, Inc., Lonza Group AG, Multiply Labs, Inc., Ori Biotech Ltd, Cytiva (Danaher Corporation), Sartorius AG, Miltenyi Biotec B.V. & Co. KG, Thermo Fisher Scientific Inc., Terumo Blood and Cell Technologies, Inc., Catalent, Inc. (Novo Holdings A/S), Charles River Laboratories International, Inc., WuXi Advanced Therapies, SK pharmteco, Inc., Samsung Biologics Co., Ltd., Resilience (National Resilience, Inc.), Landmark Bio, Mytos Bio Ltd, AGC Biologics, Oxford Biomedica plc, Genezen Laboratories, Inc., Aldevron, LLC (Danaher), Andelyn Biosciences, Inc., Bristol Myers Squibb Company, Kite Pharma, Inc. (Gilead Sciences, Inc.), Novartis AG, AstraZeneca PLC, Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics AG, Galapagos NV, Cabaletta Bio, Inc., Sonoma Biotherapeutics, Inc., City of Hope, Stanford Center for Definitive and Curative Medicine, Blood Centers of America, Inc., the Alliance for Regenerative Medicine, BlackRock, Inc., Eclipse Ventures, T. Rowe Price Group, Inc., Baillie Gifford & Co., EDBI Pte. Ltd., Gates Frontier and Prime Radiant Partners. The brief profiles representative players in each archetype and assesses which are positioned to industrialise cell and gene therapy manufacturing.

The competitive landscape is forming around six archetypes. Automated platform operators and robotics suppliers. Integrated cell and gene therapy CDMOs. Equipment, single-use and consumables suppliers. Vector, plasmid and material producers. Therapy developers with in-house or contracted manufacturing. Hospital and regional manufacturing networks, regulators and investors. Competitive intensity is high in 2026 as conventional capacity contracts and automated capacity arrives, and is expected to consolidate around platform ecosystems through 2030.

Where value migrates.

In 2026 value sits in conventional contract manufacturing, single-use consumables and vector supply, with automated platforms at clinical scale. By 2030 it moves to automated platform capacity and its consumables, integrated CDMOs that adopted automation, platform-based approvals and decentralised production near treatment centres. By 2036 it settles in platform operators and their ecosystems, a few integrated CDMOs, vector and analytics suppliers and hospital manufacturing networks. Conventional open-process capacity and stand-alone vector plants without cost advantage lose ground.

Capital is moving to automation and away from conventional capacity: Cellares' USD 257 million round extended to about USD 327 million, Multiply Labs' USD 75 million, Bristol Myers Squibb's USD 380 million agreement and AstraZeneca's evaluation, against Catalent's Gosselies closure, Charles River's Hanover closure, Thermo Fisher's viral vector cuts and the AmplifyBio and Caribou shutdowns. Clinical signals include first contract doses from an automated platform (April 2026), Cabaletta and Sonoma autoimmune programmes and Galapagos' seven-day vein-to-vein decentralised model. Patent and research activity centres on closed-process automation, release assays, non-viral delivery, vector productivity and digital batch control. The brief tracks four indicators: Smart Factory commercial throughput in 2027, the first approval on platform manufacturing data, decentralised manufacturing licences and cost of goods per autologous dose.

The United States leads on platforms, regulation and capital; Europe hosts Lonza, Sartorius, Miltenyi and the Leiden site; Japan, Singapore and South Korea add capacity and investment; China's capacity serves domestic programmes. Oncology CAR-T, autoimmune cell therapy, gene-edited stem cell and gene therapy vectors are the first demand pools.